GlassScriptPhysician profile
Allison K Brown
NPI 1023729605
$7,267.80
in general payments reported to CMS, 2019-2025
27 companies · $3,148 in 2025
The $3,148 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,552 · 2024: $2,567 · 2025: $3,148.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,852 · Education: $416.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,851.94 |
| Education | $415.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,757.66 | 2023-2025 | |
| Janssen Biotech, INC. | $612.04 | 2023-2025 | Tremfya |
| E.R. Squibb & Sons, L.L.C. | $516.43 | 2023-2025 | Sotyktu |
| Novartis Pharmaceuticals Corporation | $455.23 | 2023-2025 | |
| Galderma Laboratories, L.P. | $429.19 | 2023-2025 | Aklief, Nemluvio, Epsolay |
| Pfizer INC. | $405.38 | 2023-2025 | |
| Arcutis Biotherapeutics, INC. | $372.86 | 2023-2025 | Zoryve |
| Lilly USA, LLC | $350.30 | 2023-2025 | Taltz, Ebglyss, Zepbound |
| Incyte Corporation | $341.77 | 2023-2025 | Opzelura |
| Ucb, INC. | $292.85 | 2023-2025 | Bimzelx |
| Dermavant Sciences, INC. | $221.72 | 2023-2024 | Vtama |
| Organon LLC | $197.39 | 2025 | Vtama |
| Regeneron Healthcare Solutions, INC. | $168.70 | 2023-2025 | Dupixent |
| Sun Pharmaceutical Industries INC. | $163.73 | 2023-2025 | Odomzo, Blu-U, Absorica Ld |
| Sanofi-Aventis U.S. LLC | $153.99 | 2023-2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $153.96 | 2023-2024 | Adbry |
| Genzyme Corporation | $139.76 | 2023-2025 | |
| Mayne Pharma Commercial LLC | $127.01 | 2023-2025 | |
| Amgen INC. | $95.81 | 2024-2025 | Otezla, Otezla |
| Almirall LLC | $78.54 | 2024-2025 | Klisyri, Seysara |
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.27 | 2024-2025 | Spevigo, Cyltezo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $41.01 | 2024-2025 | Siliq, Cabtreo |
| Biofrontera INC. | $39.48 | 2023-2024 | Ameluz, Xepi, Bf-Rhodoled |
| Botanix Sb INC | $31.94 | 2025 | Sofdra |
| Journey Medical Corporation | $30.47 | 2023-2025 | |
| Solta Medical, A Division of Bausch Health US, LLC | $29.33 | 2025 | |
| Verrica Pharmaceuticals INC. | $18.98 | 2023 | Ycanth |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allison Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.